Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc > IBio

<< Previous

Bullboard Posts

Next >>

Post by Patienceiskeeon Sep 29, 2020 7:31am

243 Views

Post# 31633895

IBio

With their proven booster technology and very renowned way of multiplying the vaccine. This will be the vaccine you can't end with. And with capacity already signed to produce a hundred million right off the Hop I believe nothing will keep the share price now so I am slowly accumulating! Please invest your money widely and don't invest your c e r b remember the vaccine will receive the most money

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario